Biotage Universal Phase Separators, Solving an Age Old Problem
Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced their new Universal Phase Separators, a flexible alternative to the traditional glass funnel separation of immiscible liquids.
Uppsala, Sweden, November 15, 2012 / B3C newswire / - Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced their new Universal Phase Separators, a flexible alternative to the traditional glass funnel separation of immiscible liquids. The Biotage Universal Phase Separation columns are fitted with a selectively permeable insert that separates aqueous phases from organic solvents under gravity; solving the age old problem of how to remove an upper organic phase from a lower aqueous phase, during a traditional liquid-liquid extraction process, without creating additional process steps.
The unique design allows the organic phase to pass through the internal frit wherever it is located, providing a universal approach to separating two liquid phases while its one-size-fits-all approach enables any volume under 80 mL to be processed in one step, or larger volumes by serial batches. Made from inert proprietary polymers, the Biotage Universal Phase Separators come in an easy-to-use kit form and refill packs, ready to use in seconds straight out of the box.
"Biotage Universal Phase Separators are the modern day alternative to separating with the glass separating funnel. Ideal for working with a range of organic solvents, or in parallel this product is economical, flexible and extremely simple to use. There are no moving parts, with nothing to prime, it's all achieved by fundamental physical principles and clever product design." says Dr. Sunil Rana, Product Manager Chemistry Applications and Resins and Work-Up Products at Biotage.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance